Skip to main content

Table 4 Adverse events (including COPD exacerbations) overall and by primary system organ class (>3% in either treatment group; Safety population)

From: Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

  Indacaterol 150 μg o.d.
N = 211
n (%)
Placebo
N = 205
n (%)
Patients with any adverse event (s) 104 (49.3) 96 (46.8)
Primary system organ class   
Respiratory, thoracic and mediastinal disorders 40 (19.0) 43 (21.0)
Infections and infestations 37 (17.5) 28 (13.7)
Gastrointestinal disorders 19 (9.0) 14 (6.8)
Musculoskeletal and connective tissue disorders 16 (7.6) 17 (8.3)
Nervous system disorders 11 (5.2) 11 (5.4)
General disorders and administration site conditions 9 (4.3) 10 (4.9)
Injury, poisoning and procedural complications 9 (4.3) 5 (2.4)
Investigations 7 (3.3) 7 (3.4)
  1. COPD = chronic obstructive pulmonary disease